1. Worlth Health Organization (WHO). Expert Committee on Specifications for Pharmaceutical Preparations. WHO technical report series N° 992. Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 2015. https://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf
2. The European Agency (EMA) for the Evaluation of Medicinal Products – Evaluation of Medicines for Human Use. Committee Proprietary Medicinal Products – Note for guidance on the investigation of bioavailability and bioequivalence. December 2000. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-investigation-bioavailability-bioequivalence_en.pdf
3. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry bioavailability and studies Submitted in NDAs or INDs general considerations. Draft guidance February 2019. https://www.fda.gov/media/121311/download
4. Davit B, Conner D, Shargel L. Drug product performance, in vivo bioavailability and bioequivalence. In: Shargel L, Yu A, editors. Applied biopharmaceutics and pharmacokinetics, 7th edn. McGraw Hill Education; 2012. p. 469–528
5. Sietsema WK. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol. 1989;27(4):179–211.